The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Revising the definition of Alzheimer's disease: a new lexicon
Open accessAbstract
Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonamnestic clinical presentations, that is, language, visuospatial, and executive disorders, may also be due to AD [63–66].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [64]
In the citing paper
“Hippocampal volume has thus been proposed as a neuroimaging biomarker for early AD diagnosis (Albert et al., 2011; Dubois et al., 2010).”
From Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia (2013) · cites this paper as Dubois et al., 2010
In the citing paper
“Because the presence of Aβ deposition significantly increases the likelihood of having AD pathology in patients with aMCI according to current diagnosis recommendations (Albert et al., 2011; Dubois et al., 2010)”
From Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia (2013) · cites this paper as Dubois et al., 2010
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citation
Cited by
Sorted by citations
Items 101–112 of 112
Marcone, A., Garibotto, V., Moresco, R. M., Florea, I., Panzacchi, A., Carpinelli, A., Virta, J. R., Tettamanti, M., Borroni, B., Padovani, A., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111748 · Cited by 51
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD expert meeting
Robert, P. H., Konig, A., Andrieu, S., Bremond, F., Chemin, I., Chung, P. C., Dartigues, J. F., Dubois, B., Feutren, G., Guillemaud, R., et al. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0046-3 · Cited by 46
Self-citationGuanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer’s disease
Liu, H., Luo, K., & Luo, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-21256-6 · Cited by 42
Multiple pathologies are common in Alzheimer patients in clinical trials
Wang, B. W., Lu, E., Mackenzie, I. R. A., Assaly, M., Jacova, C., Lee, P. E., Beattie, B. L., & Hsiung, G. Y. R. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015316 · Cited by 41
Self-citationSchelle, J., Häsler, L. M., Göpfert, J. C., Joos, T. O., Vanderstichele, H., Stoops, E., Mandelkow, E., Neumann, U., Shimshek, D. R., Staufenbiel, M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.005 · Cited by 40
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
Tau in Late-Life Depression: A Systematic Review and Meta-Analysis
Brown, E. E., Iwata, Y., Chung, J. K., Gerretsen, P., & Graff-Guerrero, A. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160401 · Cited by 29
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Preventing cognitive decline in preclinical Alzheimer's disease
Riedel, W. J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.10.002 · Cited by 22
Beauchet, O., Launay, C. P., Chabot, J., Levinoff, E. J., & Allali, G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160604 · Cited by 15
Diagnosing progressive supranuclear palsy: Role of biological and neuroimaging markers
Benussi A, B. B. (2014) · Journal of Alzheimer's Disease & Parkinsonism · doi:10.4172/2161-0460.1000168 · Cited by 6
“In Alzheimer’s disease, CSF analyses show a typical decrease in amyloid β42 (Aβ42), and an increase in tau (t-tau) and phospho-tau (p-tau) levels compared with controls and other neurodegenerative diseases [45-47].”
Background
Metadata
- Authors
- Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., Gauthier, S., Hampel, H., Jicha, G. A., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Sarazin, M., de Souza, L. C., Stern, Y., Visser, P. J., & Scheltens, P.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- University of British Columbia (CA)
- University of California, Los Angeles (US)
- University of Virginia (US)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- UCL Queen Square Institute of Neurology (GB)
- University of California San Diego (US)
- Douglas Mental Health University Institute (CA)
- Goethe University Frankfurt (DE)
- University of Kentucky (US)
- Tohoku University (JP)
- Newcastle University (GB)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- NewYork–Presbyterian Hospital (US)
- Maastricht University Medical Centre (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Dubois, Bruno
- ORCID
- Dubois, Bruno
- Feldman, Howard H
- Jacova, Claudia
- Cummings, Jeffrey L
- DeKosky, Steven T
- Frisoni, Giovanni
- Fox, Nick C
- Galasko, Douglas
- Gauthier, Serge
- Hampel, Harald
- Jicha, Gregory A
- Meguro, Kenichi
- O'Brien, John
- Pasquier, Florence
- Robert, Philippe
- Rossor, Martin
- Sarazin, Marie
- Stern, Yaakov
- Visser, Pieter J
- Scheltens, Philip
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 9
- Issue
- 11
- Pages
- 1118-1127
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2157110881
- Semantic Scholar
- 05f87cd51d602a643bf8f0ce8468ef827dda6a1b
- Cited by
- 1,869
- References
- 94
- Citations by year
- 2026: 27 · 2025: 56 · 2024: 67 · 2023: 66 · 2022: 63 · 2021: 80 · 2020: 104 · 2019: 97 · 2018: 109 · 2017: 128 · 2016: 134 · 2015: 144 · 2014: 203 · 2013: 209 · 2012: 213
- FWCI
- 128.35
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10123)
- Eisai
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, diagnostic criteria, disease definition, vocabulary, biomarkers, pre-dementia, dementia, cognitive impairment, clinical spectrum
- MeSH terms
- Alzheimer Disease, Chicago, Dementia, Humans, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
